Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Zhejiang Provincial People's Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
University of Washington
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Cancer Institute, Egypt
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Baylor College of Medicine
City of Hope Medical Center
City of Hope Medical Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
Roswell Park Cancer Institute
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University of Turin, Italy
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Yale University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)